查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886994

mRNA療法市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，以及2024年至2032年的預測

mRNA Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 151 Pages | 商品交期: 請詢問到貨日

價格

mRNA療法市場成長驅動因子

全球mRNA療法市場正經歷快速發展，這得益於前所未有的科學進步、不斷擴展的生物技術以及在新冠疫情期間mRNA疫苗的成功商業化。根據最新的市場研究，在強勁的研發活動和mRNA疫苗日益普及的推動下，全球mRNA療法市場預計將在2024年達到89.1億美元。然而，隨著新冠疫苗需求的正常化和全球疫苗接種計畫的調整，預計到2025年，該市場規模將萎縮至60.1億美元。儘管目前市場暫時萎縮，但在創新、治療應用拓展和研發管線加速的推動下，預計到2032年，mRNA市場將快速增長至214.5億美元，2025年至2032年的複合年增長率將達到19.9%。

mRNA技術從根本上改變了製藥業的格局。曾經被視為實驗性平台的mRNA技術，如今已迅速發展成為傳染病、癌症、罕見遺傳疾病和個人化醫療領域的變革性技術。 mRNA新冠疫苗Comirnaty（輝瑞/BioNTech）和Spikebax（Moderna）的成功上市，充分展現了mRNA療法的潛力，並在全球市場樹立了良好的口碑。

北美地區在2024年以35.12%的市場佔有率（價值31.3億美元）引領全球市場，這得益於世界一流的研究基礎設施、充足的公共和私人資金，以及Moderna、輝瑞、BioNTech和葛蘭素史克等主要製藥創新企業的強大實力。

2025年的下滑反映了新冠疫苗接種活動的縮減。然而，從2026年開始，隨著各種研發管線接近商業化，預計市場將再次實現強勁的兩位數成長。

推動市場成長的因素

1. mRNA療法的優點

與小分子化合物、DNA疫苗和傳統生物製劑相比，mRNA療法具有若干獨特的優勢。

  • 快速的研發週期
  • 強大的免疫反應
  • 安全性優勢（不整合到宿主基因組）
  • 低劑量高效
  • 對新株的高適應性

這些優勢正在加速針對流感、呼吸道合胞病毒（RSV）、痘病毒、寨卡病毒、瘧疾和愛滋病等傳染病的mRNA疫苗的研發。癌症疫苗和蛋白質替代療法領域也取得了進展。

2.應用領域拓展至疫苗以外

雖然疫苗目前佔市場收入的主導地位，但mRNA療法正在拓展至以下領域：

  • 腫瘤學（例如，個人化癌症疫苗）
  • 遺傳性疾病（例如，酵素替代療法）
  • 蛋白質療法
  • 心血管疾病
  • 自體免疫疾病

預計從2027年起，製藥領域將成為成長最快的類別，首個mRNA藥物預計將於2027年上市，mRNA藥物市場預計將在2027年至2032年間以118.7%的複合年增長率增長，到2032年達到20億美元。

市場限制因子

1. 儲存與穩定性挑戰

mRNA分子需要超低溫才能維持穩定性。這阻礙了冷鏈基礎設施有限的地區，特別是低收入國家，採用mRNA技術。

2. 高昂的生產成本

mRNA的生產涉及以下流程：

  • 多重純化工藝
  • 專用設施
  • 複雜的脂質奈米顆粒（LNP）製劑
  • 嚴格的監理合規要求

這些因素需要大量的資本投入，並限制了全球產能。

3. 監管與公眾接受度的挑戰

mRNA藥物的監管框架仍在不斷發展中。儘管有強而有力的科學支持，但部分人士仍持懷疑態度，尤其是在新型疫苗技術方面。

主要市場趨勢

mRNA在藥物研發的應用日益廣泛

全球臨床試驗數量顯著成長，截至2022年，約40%的I期臨床試驗是基於mRNA技術。企業將mRNA應用於以下領域：

  • 個人化癌症疫苗
  • 腫瘤內注射
  • 免疫療法

眾多合作、收購和協作表明，整個產業正在建立強大的研發管線。

遞送技術的突破性創新

脂質奈米顆粒 (LNP)、聚合物和陽離子奈米顆粒正在推動以下方面的改進：

  • mRNA 穩定性
  • 標靶遞送
  • 細胞攝取

這些創新降低了毒性，並擴大了治療應用範圍。

市場區隔分析

依類型

預防（疫苗）－預計 2024 年市佔率最大

預計 2024 年，疫苗細分市場將佔最大的市場佔有率，這主要得益於 COVID-19 疫苗和呼吸道合胞病毒 (RSV) 疫苗的批准。

已核准的產品包括：

  • Comirnaty（輝瑞/BioNTech）
  • Spikebax（Moderna）
  • mRESVIA（Moderna - 呼吸道合胞病毒疫苗）

正在研發的非新冠疫苗包括：

  • 季節性流感疫苗（mRNA-1010）
  • 猴痘疫苗
  • 瘧疾疫苗
  • 鉅細胞病毒 (CMV) 疫苗

藥物/藥物 - 成長最快的領域

隨著 mRNA 療法的商業化，預計從 2027 年起將快速成長，尤其是在腫瘤領域。

依應用領域

傳染病領域 - 截至目前處於領先地位2024年

該領域佔領先地位，因為截至2025年初，所有核准的mRNA產品均針對傳染病。

腫瘤領域－高成長領域

多種癌症疫苗正在研發中，包括BioNTech公司用於治療非小細胞肺癌（NSCLC）的BNT116。

依分銷管道

  • 由於疫苗接種計劃，醫院藥房將在2024年發揮主導作用。
  • 隨著核准產品的增加，零售藥局預計也將成長。

區域展望

北美 - 市場領導者（2024 年市場規模：31.3 億美元）

主要驅動因素

  • 大量政府資金支持（例如，2025 年 Moderna 獲得 5.9 億美元資助）
  • 強大的生物技術新創企業生態系統
  • 快速的監管審批
  • 高度的認知度與應用率

歐洲

德國和法國引領該地區，是 BioNTech、CureVac 和賽諾菲等主要公司的所在地。

亞太地區

這是成長最快的地區，主要受以下因素驅動：

  • 中國於2023年核准了首款國產mRNA新冠疫苗
  • 對癌症治療測試的大量投資
  • 製造與研發合作

其他

隨著拉丁美洲、中東和非洲醫療基礎設施的發展，這些地區對疫苗的興趣日益濃厚。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 概述：mRNA技術的進展
  • mRNA療法的未來成長前景
  • 主要公司產品線分析
  • 主要產業趨勢，包括併購和合作
  • 關稅對市場的影響

第五章：全球mRNA療法市場分析、洞察與展望預測（2019-2032）

  • 市場分析、洞察與預測 - 依類型劃分
    • 預防性藥物（疫苗）
      • 新冠疫苗
      • 非新冠疫苗
    • 藥品
  • 市場分析、洞察與預測 - 依應用劃分
    • 腫瘤學
    • 傳染病
    • 其他
  • 市場分析、洞察與預測 - 依分銷管道劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北部美洲
    • 歐洲
    • 亞太地區
    • 其他

第六章 北美mRNA療法市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲mRNA療法市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區

第八章 亞太地區mRNA療法市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：其他mRNA療法市場分析、洞察與預測（2019-2032）

第十章：競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
  • Moderna Inc.
  • BioNTech
  • 輝瑞公司
  • CureVac SE
  • 葛蘭素史克公司
  • 賽諾菲
  • Omega Therapeutics
  • Strand治療學
  • 免疫治療學
Product Code: FBI113411

Growth Factors of mRNA therapeutics Market

The global mRNA therapeutics market is undergoing a period of rapid evolution, driven by unprecedented scientific advancements, expanding biotechnology capabilities, and successful commercialization of mRNA-based vaccines during the COVID-19 pandemic. According to the latest market intelligence, the global mRNA therapeutics market size reached USD 8.91 billion in 2024, supported by robust R&D activities and rising acceptance of mRNA vaccines. However, the market is projected to decrease to USD 6.01 billion in 2025 due to normalization in COVID-19 vaccine demand and shifts in immunization programs worldwide. Despite this temporary contraction, the market is expected to surge to USD 21.45 billion by 2032, driven by innovation, expanding therapeutic applications, and accelerating pipeline development, achieving a CAGR of 19.9% between 2025 and 2032.

The mRNA field has fundamentally reshaped the pharmaceutical landscape. What was once considered an experimental platform has rapidly emerged as a transformational technology capable of addressing infectious diseases, cancer, rare genetic disorders, and personalized medicine. The successful deployment of mRNA COVID-19 vaccines-Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna)-validated the potential of mRNA-based therapeutics and established strong global market confidence.

North America dominated the global market with a 35.12% share in 2024, valued at USD 3.13 billion, owing to its world-leading research infrastructure, substantial public and private funding, and strong presence of major pharmaceutical innovators such as Moderna, Pfizer, BioNTech, and GSK.

The decline in 2025 reflects reduced COVID-19 vaccination campaigns. However, post-2026, the market is anticipated to return to strong double-digit expansion as diverse pipelines move closer to commercialization.

Drivers Shaping Market Growth

1. Advantages of mRNA Therapeutics

mRNA therapies offer several unique advantages over small molecules, DNA vaccines, and conventional biologics:

  • Rapid development timeline
  • Strong immune response
  • Safety advantages (no integration into host genome)
  • High potency with small dosages
  • Easy adaptability to new strains

These benefits are accelerating the development of mRNA vaccines for infectious diseases like influenza, RSV, Mpox, Zika, malaria, and HIV, as well as therapeutic vaccines for cancer and protein-replacement therapies.

2. Expanding Applications Beyond Vaccines

Though vaccines dominate current market revenues, mRNA therapies are expanding into:

  • Oncology (e.g., personalized cancer vaccines)
  • Genetic diseases (e.g., enzyme replacement therapies)
  • Protein therapy
  • Cardiovascular disease
  • Autoimmune disorders

The drugs/medications segment is expected to become the fastest-growing category post-2027, supported by the anticipated launch of the first mRNA drug in 2027 and projections that the mRNA drug market will reach USD 2 billion by 2032 at a CAGR of 118.7% from 2027 to 2032.

Market Restraints

1. Storage and Stability Challenges

mRNA molecules require ultra-cold temperatures for stability. This continues to hinder adoption in regions with limited cold-chain infrastructure, particularly low-income countries.

2. High Manufacturing Costs

mRNA production involves:

  • Multiple purification steps
  • Specialized facilities
  • Complex lipid nanoparticle (LNP) formulation
  • Stringent regulatory compliance

These factors contribute to high capital expenditures and limited global production capacity.

3. Regulatory and Public Acceptance Issues

The regulatory framework for mRNA drugs is still evolving. Despite strong scientific backing, skepticism persists among certain segments of the population, particularly regarding new vaccine technologies.

Key Market Trends

Growing Adoption of mRNA in Drug Development

There has been substantial growth in clinical trials globally, with approximately 40% of mRNA-based clinical trials in Phase I as of 2022. Companies are using mRNA for:

  • Personalized oncology vaccines
  • Intratumoral injections
  • Immunotherapies

Multiple partnerships, acquisitions, and collaborations indicate a strong pipeline across the industry.

Breakthrough Innovations in Delivery Technologies

LNPs, polymers, and cationic nanoparticles are improving:

  • mRNA stability
  • Targeted delivery
  • Cellular uptake

These innovations reduce toxicity and allow broader therapeutic applications.

Segmentation Analysis

By Type

Prophylactic (Vaccines) - Dominant in 2024

The vaccines segment accounted for the highest share in 2024 due to COVID-19 and RSV vaccine approvals.

Approved products include:

  • Comirnaty (Pfizer/BioNTech)
  • Spikevax (Moderna)
  • mRESVIA (Moderna - RSV vaccine)

Non-COVID vaccines in the pipeline include:

  • Seasonal influenza (mRNA-1010)
  • Mpox
  • Malaria
  • Cytomegalovirus (CMV)

Drugs/Medications - Fastest Growing Segment

Expected boom after 2027 as mRNA therapeutics enter commercialization, especially in oncology.

By Application

Infectious Diseases - Leading in 2024

Because all approved mRNA products as of early 2025 target infectious diseases, this segment dominates.

Oncology - High Future Growth

Multiple cancer vaccines are in development, including BioNTech's BNT116 for NSCLC.

By Distribution Channel

  • Hospital Pharmacies dominated in 2024 due to vaccination programs.
  • Retail Pharmacies expected to grow with broader product approvals.

Regional Outlook

North America - Market Leader (2024 Value: USD 3.13 Billion)

Key drivers:

  • Significant government funding (e.g., USD 590 million to Moderna in 2025)
  • Strong biotech startup ecosystem
  • Rapid regulatory approvals
  • High awareness and adoption

Europe

Germany and France lead the region with major companies such as BioNTech, CureVac, and Sanofi.

Asia Pacific

Fastest-growing region, driven by:

  • China's approval of its first homegrown mRNA COVID-19 vaccine in 2023
  • High investment in oncology trials
  • Partnerships for manufacturing and development

Rest of the World

Latin America and Middle East & Africa show rising interest as healthcare infrastructure improves.

Competitive Landscape

Major players include:

  • Moderna Inc.
  • BioNTech SE
  • Pfizer Inc.
  • CureVac SE
  • GSK plc.
  • Sanofi
  • Omega Therapeutics
  • Strand Therapeutics

These companies are investing heavily in:

  • Clinical pipeline expansion
  • Delivery technology innovation
  • Large-scale biomanufacturing facilities
  • Cross-border partnerships

Conclusion

The global mRNA therapeutics market is transforming rapidly, driven by technological innovation, expanded pipeline applications, rising funding, and growing acceptance of mRNA-based medicines. While the market dips from USD 8.91 billion in 2024 to USD 6.01 billion in 2025, it is set to rebound strongly, reaching USD 21.45 billion by 2032. With breakthroughs expected across oncology, infectious diseases, and rare genetic disorders, mRNA technology is positioned to become one of the most influential healthcare innovations of the 21st century.

Segmentation

By Type

  • Prophylactic (Vaccines)
    • COVID-19 Vaccines
    • Non-COVID-19 Vaccines
  • Drugs/Medications

By Application

  • Oncology
  • Infectious Diseases
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Others

By Region

  • North America (By Type, Application, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Type, Application, Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Advancements in mRNA Technology
  • 4.2. Future Growth Prospects for mRNA Therapeutics
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Impact of Tariff on the Market

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Prophylactic (Vaccines)
      • 5.1.1.1. COVID-19 Vaccines
      • 5.1.1.2. Non-COVID-19 Vaccines
    • 5.1.2. Drugs/Medications
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Oncology
    • 5.2.2. Infectious Diseases
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Drug Stores & Retail Pharmacies
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Prophylactic (Vaccines)
      • 6.1.1.1. COVID-19 Vaccines
      • 6.1.1.2. Non-COVID-19 Vaccines
    • 6.1.2. Drugs/Medications
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Oncology
    • 6.2.2. Infectious Diseases
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Drug Stores & Retail Pharmacies
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Prophylactic (Vaccines)
      • 7.1.1.1. COVID-19 Vaccines
      • 7.1.1.2. Non-COVID-19 Vaccines
    • 7.1.2. Drugs/Medications
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Oncology
    • 7.2.2. Infectious Diseases
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Drug Stores & Retail Pharmacies
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Prophylactic (Vaccines)
      • 8.1.1.1. COVID-19 Vaccines
      • 8.1.1.2. Non-COVID-19 Vaccines
    • 8.1.2. Drugs/Medications
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Oncology
    • 8.2.2. Infectious Diseases
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drug Stores & Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Prophylactic (Vaccines)
      • 9.1.1.1. COVID-19 Vaccines
      • 9.1.1.2. Non-COVID-19 Vaccines
    • 9.1.2. Drugs/Medications
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Oncology
    • 9.2.2. Infectious Diseases
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Drug Stores & Retail Pharmacies
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Pfizer Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. CureVac SE
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. GSK plc
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Sanofi
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Omega Therapeutics
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Strand Therapeutics
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Immunomic Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 3: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 4: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 7: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 8: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 9: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 12: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 13: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 17: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 18: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 19: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 22: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2019-2032
  • Table 23: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 24: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

List of Figures

  • Figure 1: Global mRNA Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global mRNA Therapeutics Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global mRNA Therapeutics Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global mRNA Therapeutics Market Value (USD billion), by Region, 2024 & 2032
  • Figure 6: North America mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 7: North America mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 8: North America mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 9: North America mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 10: North America mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America mRNA Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America mRNA Therapeutics Market Value Share (%), By Country, 2024
  • Figure 14: Europe mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 15: Europe mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 16: Europe mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 17: Europe mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 18: Europe mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 23: Asia Pacific mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 24: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 25: Asia Pacific mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 26: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Rest of the World mRNA Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 31: Rest of the World mRNA Therapeutics Market Value Share (%), by Type, 2024
  • Figure 32: Rest of the World mRNA Therapeutics Market Value (USD billion), by Application, 2024 & 2032
  • Figure 33: Rest of the World mRNA Therapeutics Market Value Share (%), by Application, 2024
  • Figure 34: Rest of the World mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Rest of the World mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Global mRNA Therapeutics Market Share (%), By Company, 2024